PD-L1 is a Diverse Molecule Regulating Both Tumor-intrinsic Signaling and Adaptive Immunosuppression

Overview

Journal Transl Cancer Res

Specialty Oncology

Date 2017 Feb 28

PMID 28239565

Citations 5

Authors

Kim A Brogden

Shireen Vali

Taher Abbasi

Affiliations

Soon will be listed here.

Citing Articles

The dual role of autophagy in the regulation of cancer treatment.

Kwantwi L Amino Acids. 2024; 56(1):7.

PMID: 38310598 PMC: 10838838. DOI: 10.1007/s00726-023-03364-4.

Producing Soluble Human Programmed Cell Death Protein-1: A Natural Supporter for CD4+T Cell Cytotoxicity and Tumor Cells Apoptosis.

Mohammadzadeh S, Khanahmad H, Esmaeil N, Eskandari N, Rahimmanesh I, Rezaei A Iran J Biotechnol. 2020; 17(4):e2104.

PMID: 32671122 PMC: 7357696. DOI: 10.30498/IJB.2019.85180.

Anti-Tumor Effects of Vitamin B2, B6 and B9 in Promonocytic Lymphoma Cells.

Mikkelsen K, Prakash M, Kuol N, Nurgali K, Stojanovska L, Apostolopoulos V Int J Mol Sci. 2019; 20(15).

PMID: 31374832 PMC: 6696026. DOI: 10.3390/ijms20153763.

Plasma soluble programmed death ligand 1 levels predict clinical response in peripheral T-cell lymphomas.

Zhang X, Liu L, Zhou S, Zhao K, Song Z, Hu G Hematol Oncol. 2019; 37(3):270-276.

PMID: 31074879 PMC: 6771895. DOI: 10.1002/hon.2636.

Predictive factors of response to immunotherapy-a review from the Spanish Melanoma Group (GEM).

Espinosa E, Marquez-Rodas I, Soria A, Berrocal A, Luis Manzano J, Gonzalez-Cao M Ann Transl Med. 2017; 5(19):389.

PMID: 29114547 PMC: 5653511. DOI: 10.21037/atm.2017.08.10.

References

Herbst R, Soria J, Kowanetz M, Fine G, Hamid O, Gordon M . Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014; 515(7528):563-7. PMC: 4836193. DOI: 10.1038/nature14011. View

Francisco L, Sage P, Sharpe A . The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010; 236:219-42. PMC: 2919275. DOI: 10.1111/j.1600-065X.2010.00923.x. View

Sharma P, Allison J . The future of immune checkpoint therapy. Science. 2015; 348(6230):56-61. DOI: 10.1126/science.aaa8172. View

Bhaijee F, Anders R . PD-L1 Expression as a Predictive Biomarker: Is Absence of Proof the Same as Proof of Absence?. JAMA Oncol. 2015; 2(1):54-5. DOI: 10.1001/jamaoncol.2015.3782. View

Pedoeem A, Azoulay-Alfaguter I, Strazza M, Silverman G, Mor A . Programmed death-1 pathway in cancer and autoimmunity. Clin Immunol. 2014; 153(1):145-52. DOI: 10.1016/j.clim.2014.04.010. View

Jiang Y, Li Y, Zhu B . T-cell exhaustion in the tumor microenvironment. Cell Death Dis. 2015; 6:e1792. PMC: 4669840. DOI: 10.1038/cddis.2015.162. View

Blank C, Haanen J, Ribas A, Schumacher T . CANCER IMMUNOLOGY. The "cancer immunogram". Science. 2016; 352(6286):658-60. DOI: 10.1126/science.aaf2834. View

Chen J, Jiang C, Jin L, Zhang X . Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Ann Oncol. 2015; 27(3):409-16. DOI: 10.1093/annonc/mdv615. View

Clark C, Gupta H, Sareddy G, Pandeswara S, Lao S, Yuan B . Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma. Cancer Res. 2016; 76(23):6964-6974. PMC: 5228566. DOI: 10.1158/0008-5472.CAN-16-0258. View

10.

Dong H, Strome S, Salomao D, Tamura H, Hirano F, Flies D . Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002; 8(8):793-800. DOI: 10.1038/nm730. View

11.

TSENG S, Otsuji M, Gorski K, Huang X, Slansky J, Pai S . B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med. 2001; 193(7):839-46. PMC: 2193370. DOI: 10.1084/jem.193.7.839. View